

I-FW



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9/9/05 Signature: *[Signature]*  
(Ginny Blundell)

Docket No.: WIBL-P01-011  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Brent R. Stockwell

Application No.: 10/767018

Confirmation No.: 4718

Filed: January 29, 2004

Art Unit: 1642

For: IDENTIFICATION OF GENOTYPE-  
SELECTIVE ANTI-TUMOR AGENTS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Application No.: 10/767018

Docket No.: WIBL-P01-011

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WIBL-P01-011.

Dated:

9/9/05

Respectfully submitted

By

Z. Angela Guo

Registration No.: 54,144

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/767018

Attorney Docket No.: WIBL-P01-011

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on

9/9/08  
Date

[Signature]  
Signature

\_\_\_\_\_  
Typed or printed name of person signing Certificate

\_\_\_\_\_  
Registration Number, if applicable

\_\_\_\_\_  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO/SB/08 (69 References)  
References (69, CA – CQ2)



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/767018
				Filing Date	January 29, 2004
				First Named Inventor	Brent R. Stockwell
				Art Unit	1642
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	WIBL-P01-011

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Ahmed, S. Ansar et al., "A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [ <sup>3</sup> H] thymidine incorporation assay", <i>Journal of Immunological Methods</i> , 170(2): 211-224 (1994) (Abstract)	
	CB	Aiken, C. T., et al., "A cell-Based Screen for Drugs to Treat Huntington's Disease", <i>Neurobiology of Disease</i> , 16:546-555 (2004)	
	CC	Andoh, T., et al., "Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I," <i>Proc Natl Acad Sci U S A</i> , 84:5565-5569 (1987).	
	CD	Bjornsti, M-A., et al., "Expression of Human DNA Topoisomerase I in Yeast Cells Lacking Yeast DNA Topoisomerase I: Restoration of Sensitivity of the Cells to the Antitumor Drug Camptothecin," <i>Cancer Res</i> , 49:6318-23 (1989).	
	CE	Bosch, F.X., et al., "The causal relation between human papillomavirus and cervical cancer," <i>J Clin Pathol</i> , 55:244-265 (2002).	
	CF	Brown, E.J., et al., "A mammalian protein targeted by G1-arresting rapamycin-receptor complex," <i>Nature</i> , 369:756-758 (1994).	
	CG	Calin, G.A., et al., "Low frequency of alterations of the $\alpha$ (PPP2R1A) and $\beta$ (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms," <i>Oncogene</i> , 19:1191-1195 (2000).	
	CH	Capdeville, R., et al., "Glivec (STI571, IMATINIB), A Rationally Developed, Targeted Anticancer Drug," <i>Nat Rev Drug Discov</i> , 1:493-502 (2002).	
	CI	Champoux, J.J., "Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I," <i>Annals New York Acad Sci</i> , 922:56-64 (2000).	
	CJ	Chan, Y-M, et al., "Caspase inhibitors promote the survival of avulsed spinal motoneurons in neonatal rats," <i>NeuroReport</i> , 12(3):541-5 (2001).	
	CK	D'Arpa, P., et al., "Involvement of Nucleic Acid Synthesis in Cell Killing Mechanisms of Topoisomerase Poisons," <i>Cancer Res</i> , 50:6919-24 (1990).	
	CL	DeVita, V.T., Jr., et al., "Principles of Cancer Management: Chemotherapy," <i>Cancer: Principles &amp; Practice of Oncology</i> , Fifth Edition, 333-347 (1997).	
	CM	Dolma, S, et al., "Identification of genotype-selective antitumor agents using synthetic lethal	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/767018
				Filing Date	January 29, 2004
				First Named Inventor	Brent R. Stockwell
				Art Unit	1642
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	WIBL-P01-011

		chemical screening in engineered human tumor cells," <i>Cancer Cell</i> , 3:285-296 (2003).	
CN		Druker, B.J. et al., "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", <i>Nature Medicine</i> , 2:561-566 (1996) (Abstract)	
CO		Elenbaas, B. et al., "Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells", <i>Genes &amp; Development</i> , 15:50-65 (2001)	
CP		Eng, W-K., et al., "Evidence that DNA Topoisomerase I Is Necessary for the Cytotoxic Effects of Camptothecin," <i>Mol Pharmacol</i> , 34:755-60 (1988).	
CQ		Hahn, W. C. and Weinberg, R. A., "Modelling the Molecular Circuitry of Cancer", <i>Nature Reviews Cancer</i> , 2:331-341 (2002)	
CR		Hahn, W.C., et al., "Creation of human tumour cells with defined genetic elements," <i>Nature</i> , 400:464-468 (1999).	
CS		Hahn, W.C., et al., "Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation," <i>Mol Cell Biol</i> , 22(7):2111-23 (2002).	
CT		Hahn, W.C., et al., "Inhibition of telomerase limits the growth of human cancer cells," <i>Nat Med</i> , 5(10):1164-1170 (1999).	
CU		Hamad, N. M. et al., "Distinct requirements for Ras oncogenesis in human versus mouse cells", <i>Genes &amp; Development</i> , 16:2045-2057 (2002)	
CV		Harley, C.B., "Telomerases," <i>Pathol Biol (Paris)</i> , 42:342-5 (1994).	
CW		Hsiang, Y-H. and Liu, L.F., "Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin," <i>Cancer Res</i> , 48:1722-6 (1988).	
CX		Hsiang, Y-H., et al., "Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin," <i>Cancer Res</i> , 49:5077-82 (1989).	
CY		Jorcyk, C.L., et al., "Development and Characterization of a Mouse Prostate Adenocarcinoma Cell Line: Ductal Formation Determined by Extracellular Matrix," <i>The Prostate</i> , 34:10-22 (1998).	
CZ		Kohn, T., et al., "Alterations of the <i>PPP1R3</i> Gene in Human Cancer," <i>Cancer Res</i> , 59:4170-4 (1999).	
CA1		Laurent, G. and Jaffrezou, J-P., "Signaling pathways activated by daunorubicin," <i>Blood</i> , 98(4):913-924 (2001).	
CB1		Lessnick, S.L., et al., "The Ewing's sarcoma oncoprotein EWS/FLI induces a p53- dependent growth arrest in primary human fibroblasts," <i>Cancer Cell</i> , 1:393-401 (2002).	
CC1		Liu, L.F., et al., "Mechanism of Action of Camptothecin," <i>Annals N Y Acad Sci</i> , 922:1-10 (2000).	
CD1		Loomis, C.R. and Bell, R.M., "Sangivamycin, a Nucleoside Analogue, Is a Potent Inhibitor of Protein Kinase C*," <i>J Biol Chem</i> , 263(4):1682-1692 (1998).	
CE1		Madden, K.R., and Champoux, J.J., "Overexpression of Human Topoisomerase I in Baby Hamster Kidney Cells: Hypersensitivity of Clonal Isolates to Camptothecin," <i>Cancer Res</i> , 52:525-32 (1992).	
CF1		Majno, G. and Joris, I., "Apoptosis, Oncosis, and Necrosis," <i>Am J Pathol</i> , 146(1):3-15 (1995).	
CG1		Makin, G., "Targeting apoptosis in cancer chemotherapy," <i>Expert Opin Ther Targets</i> , 6(1):73-84 (2002).	
CH1		Miller, M.L. and Ojima, I., "Chemistry and Chemical Biology of Taxane Anticancer Agents," <i>Chem. Record</i> , 1:195-211 (2001).	
CI1		Millward, T.A., et al., "Regulation of protein kinase cascades by protein phosphatase 2A," <i>Trends Biochem Sci</i> , 24:186-91 (1999).	
CJ1		Mokbel, K. and Hassanally, D., "From HER2 to Herceptin," <i>Curr Med Res Opin</i> , 17(1):51-9 (2001).	
CK1		Müller, I., et al., "Anthracycline-derived chemotherapeutics in apoptosis and free radical	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/767018
				Filing Date	January 29, 2004
				First Named Inventor	Brent R. Stockwell
				Art Unit	1642
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	WIBL-P01-011

		cytotoxicity (Review), <i>Int J Mol Med</i> , 1:491-4 (1998).	
CL1		Nociari, M.M., <i>et al.</i> , "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity," <i>J. Immunol. Methods</i> , 213:157-167 (1998).	
CM1		Pallas, D.C., <i>et al.</i> , "Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A," <i>Cell</i> , 60:167-176 (1990)	
CN1		Perez-Stable, C., <i>et al.</i> , "Prostate Cancer Progression, Metastasis, and Gene Expression in Transgenic Mice," <i>Cancer Res</i> , 57:900-6 (1997).	
CO1		Rao, K.V., "Structure of Sangivamycin," <i>J Med Chem</i> , 11:939-41 (1968).	
CP1		Rich, J.N., <i>et al.</i> , "A Genetically Tractable Model of Human Glioma Formation," <i>Cancer Res</i> , 61:3556-60 (2001).	
CQ1		Richard, D., <i>et al.</i> , "Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines," <i>Leukemia Res</i> , 26:927-931 (2002).	
CR1		Ruediger, R., <i>et al.</i> , "Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A $\beta$ subunit gene," <i>Oncogene</i> , 20:1892-1899 (2001).	
CS1		Ruediger, R., <i>et al.</i> , "Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A $\alpha$ subunit gene," <i>Oncogene</i> , 20:10-15 (2001).	
CT1		Sabatini, D.M., <i>et al.</i> , "RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs," <i>Cell</i> , 78:35-43 (1994)	
CU1		Sandmoller, A., <i>et al.</i> , "A Transgenic Mouse Model for Lung Adenocarcinoma," <i>Cell Growth &amp; Differ</i> , 6:97-103 (1995).	
CV1		Schreiber, S.L., "Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry, <i>Bioorg. Med. Chem.</i> , 6:1127-1152 (1998).	
CW1		Sellers, W.R. and Kaelin, W.G., "Role of the retinoblastoma protein in the pathogenesis of human cancer," <i>J Clin Oncol</i> , 15:3301-3312 (1997).	
CX1		Shawver, L.K., <i>et al.</i> , "Smart drugs: Tyrosine kinase inhibitors in cancer therapy," <i>Cancer Cell</i> , 1:117-123 (2002).	
CY1		Sherr, C.J., "The <i>INK4a</i> /ARF Network in Tumour Suppression," <i>Nat Rev Mol Cell Biol</i> , 2:731-737 (2001).	
CZ1		Shi, Y., <i>et al.</i> , "Enhanced Sensitivity of Multiple Myeloma Cells Containing <i>PTEN</i> Mutations to CCI-779," <i>Cancer Res</i> , 62:5027-34 (2002).	
CA2		Simons, A., <i>et al.</i> , "Establishment of a Chemical Synthetic Lethality Screen in Cultured Human Cells," <i>Genome Res</i> , 11:266-273 (2001).	
CB2		Stockwell, B. R., "Chemical Genetic Screening Approaches to Neurobiology," <i>Neuron</i> , 36:559-562 (2002).	
CC2		Stockwell, B. R., "Frontiers in chemical genetics", <i>Trends Biotechnol</i> 18, 449-55, (2000)	
CD2		Stockwell, B.R., "Chemical Genetics: Ligand-Based Discovery of Gene Function, <i>Nat Rev Genet</i> , 1:116-125 (2000).	
CE2		Stockwell, B.R., "The biological magic behind the bullets," <i>Nature Biotechnology</i> , 22(1):37-38 (2004).	
CF2		Stockwell, B.R., <i>et al.</i> , "High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications," <i>Chem Biol</i> , 6:71-83 (1999).	
CG2		Testa, J.R. and Giordano, A., "SV40 and cell cycle perturbations in malignant mesothelioma," <i>Seminars In Cancer Biol</i> , 11:31-8 (2001).	
CH2		Torrance, C.J., <i>et al.</i> , "Use of isogenic human cancer cells for high-throughput screening and drug discovery," <i>Nat Biotechnol</i> , 19:940-945 (2001).	
CI2		Traganos, F., <i>et al.</i> , "Induction of Apoptosis by Camptothecin and Topotecan," <i>Ann N Y Acad Sci</i> , 803:101-10 (1996).	
CJ2		Tsao, Y-P., <i>et al.</i> , "Interaction between Replication Forks and Topoisomerase I-DNA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/767018
				Filing Date	January 29, 2004
				First Named Inventor	Brent R. Stockwell
				Art Unit	1642
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	WIBL-P01-011

		Cleavable Complexes: Studies in a Cell-free SV40 DNA Replication System," <i>Cancer Res</i> , 53:5908-14 (1993).	
	CK2	Van Dyke, M. M. and Dervan, Peter B., "Echinomycin Binding Sites on DNA", <i>Science</i> 225:1122-1127 (1984)	
	CL2	Vonsattel J.P.G., "Neuropathology of Huntington's Disease," <i>Neuroscience News</i> , 3(2-3):45-53 (2000).	
	CM2	Wang, S.S., <i>et al.</i> , "Alterations of the <i>PPP2R1B</i> Gene in Human Lung and Colon Cancer," <i>Science</i> , 282:284-287 (1998).	
	CN2	Wang, X. M. <i>et al.</i> , "A new microcellular cytotoxicity test based on calcein AM release", <i>Human Immunology</i> , 37(4):264-270 (1993) (Abstract)	
	CO2	Waring, M.J. and Wakelin, L.P.G., "Echinomycin: a bifunctional intercalating antibiotic," <i>Nature</i> , 252:653-7 (1974).	
	CP2	Weinstein, J.N., <i>et al.</i> , "An Information-Intensive Approach to the Molecular Pharmacology of Cancer," <i>Science</i> , 275:343-349 (1997).	
	CQ2	Zalacain, M., <i>et al.</i> , "The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells," <i>FEBS Lett</i> , 148(1):95-97 (1982).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--